{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:33:15Z","timestamp":1769632395249,"version":"3.49.0"},"reference-count":14,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T00:00:00Z","timestamp":1215648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Background\u2003<\/jats:bold> Venlafaxine is an inhibitor of neuronal serotonin and noradrenaline re\u2010uptake and a weak inhibitor of dopamine re\u2010uptake. There was no indication of problems of abuse\/dependence during the clinical trials.<\/jats:p><jats:p><jats:bold>Case description\u2003<\/jats:bold> A 53\u2010year\u2010old client with a history of alcohol and amineptine misuse and a long history of recurrent depression, for which he was prescribed venlafaxine tablets. Over time, he increased the dosage to 50 tablets daily (3750\u2003mg). Large venlafaxine dosages produced amphetamine\u2010like effects, due possibly to the related increase in dopamine turnover. Once hospitalized for detoxification, the patient had a symptomatology which was consistent with a serotonergic discontinuation syndrome.<\/jats:p><jats:p><jats:bold>Conclusions\u2003<\/jats:bold> Physicians should be aware that patients with a history of drug and alcohol abuse might develop venlafaxine dependence.<\/jats:p>","DOI":"10.1111\/j.1360-0443.2008.02266.x","type":"journal-article","created":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T16:02:52Z","timestamp":1215705772000},"page":"1572-1574","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse"],"prefix":"10.1111","volume":"103","author":[{"given":"Gianluca","family":"Quaglio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Lugoboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,8,7]]},"reference":[{"key":"e_1_2_4_2_2","unstructured":"Wyeth.Venlafaxine hydrochloride. Product's label. Philadelphia PA USA2006."},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200302203480822"},{"key":"e_1_2_4_4_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/026988119901300321"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(94)90608-4"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200004000-00026"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.paf.0000154111.69255.ab"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550490490512898"},{"key":"e_1_2_4_10_2","first-page":"S58","article-title":"Misuse of tianeptine: five cases of abuse","volume":"154","author":"Leterme L.","year":"2003","journal-title":"Ann Med Interne"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.01828.x"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-8663(00)80048-X"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7161.787a"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00298-6"},{"key":"e_1_2_4_15_2","volume-title":"The FDA Medical Products Reporting Program. Summary of Safety\u2010Related Drug Labelling Changes Approved by FDA","author":"Medwatch","year":"2000"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1360-0443.2008.02266.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1360-0443.2008.02266.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:45:13Z","timestamp":1698720313000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1360-0443.2008.02266.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,7]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1360-0443.2008.02266.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02266.x","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,7]]},"assertion":[{"value":"2008-08-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}